Nature Reviews Gastroenterology & Hepatology

Article	Citations
Genetic factors in alcohol-related cirrhosis	1160
Crosstalk between enteric neurons and colorectal cancer stem cells influences self-renewal	864
Regulating protease homeostasis in irritable bowel syndrome	695
Detecting gut osmolality changes to quench thirst	584
No beneficial effect of G-CSF in treating ACLF	531
Showing a sensitive side	459
Understanding remodelling of bile ducts to promote polycystic liver disease	403
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	378
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	340
The challenges facing female transplant hepatologists as young faculty	313
Rectally shed SARS-CoV-2 lacks infectivity: time to rethink faecal–oral transmission?	311
Hybrid EASL Congress 2023	288
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	288
Neuropod cells — sensing a sweet spot in the gut	284
Western lifestyle, metaflammation and the cell of origin of colon cancer	282
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	280
Hybrid APASL meeting 2024	260
Artificial intelligence and automation in endoscopy and surgery	242
Pouchitis: pathophysiology and management	234
Genetics, pathobiology and therapeutic opportunities of polycystic liver disease	233
Effect of bariatric surgery on risk of oesophagogastric cancer	232
A role for the gut microbiota in immune checkpoint inhibitor-induced colitis	223
Justice, equity, diversity and inclusion in gastroenterology and hepatology	199
Mapping neuroimmune interactions in the gut	192
Anti-SARS-CoV-2 vaccine in liver transplantation	181

Promoting allyship to support and uplift the LGBTQIA+ community	176
Rhythmicity of infant microbiota and dietary effects	171
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	160
Insight into virome development	158
Long-term normothermic liver perfusion	152
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	151
Human hepatocyte organoids model early NAFLD	143
Zolbetuximab treatment in metastatic gastric cancer	143
Comparing elimination diet therapies for eosinophilic oesophagitis	139
A serious side to social media	135
Sphingolipids in hepatic metabolism	133
Molecular landscape of NASH-HCC	130
A gut–liver axis in intestinal stem cell fitness	129
2023 FDA approvals in gastroenterology and hepatology	125
Disability inclusion in research and health care	123
Contrasting aspects of human excreta	123
Metabolism of 5-ASA by the gut microbiome	121
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity	119
High-density lipoprotein lipidome: a neglected source of hepatic lipids	119
Fetal liver development and implications for liver disease pathogenesis	117
Exploring liver cancer biology through functional genetic screens	113
ZBTB46+ ILC3s promote intestinal health	109
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	107
Vaccination at the forefront of the fight against hepatitis B and C	107
Author Correction: The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	104
Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	103
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease	102
Achieving health equity in liver disease pharmacotherapy	97
Hepatitis D virus: more attention needed	95
Single-cell RNA sequencing in pancreatic cancer	94
Is less more? Challenging dogma for individualized fluid resuscitation	91
Medical images, social media and consent	91
Author Correction: Improving IBD outcomes in the era of many treatment options	90
Dietary and metabolic effects on intestinal stem cells in health and disease	88
Role of steatotic liver disease in prediction and prevention of cardiometabolic diseases	87
Inter-disciplinary collaboration for innovation in gastroenterology	86
Jumping the chasm from postdoc to PI	86
Alcohol-free and low-strength drinks: friend or foe?	85
Microbial cues stimulate linear growth in undernourished mice	81
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	81
Striving to optimize colorectal cancer prevention	81
Microbiota-based biomarkers and therapeutics for cancer management	80
Metabolic health across the ages: how microbiota members support our well-being	80
Author Correction: Current and future colorectal cancer screening strategies	78
Digestive Disease Week 2022	78
Long-term dynamic ex vivo organ preservation	77
Machine perfusion of the liver: applications in transplantation and beyond	75
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease	75
Hippo signalling in the liver: role in development, regeneration and disease	73
A Roadmap for the Human Gut Cell Atlas	72

Intestinal organ chips for disease modelling and personalized medicine	69
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	67
Nomenclature of HBV core protein-targeting antivirals	61
Re-examining chemically defined liquid diets through the lens of the microbiome	60
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	60
Leveraging diet to engineer the gut microbiome	59
Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis	58
Macrophages in intestinal homeostasis and inflammatory bowel disease	58
Global epidemiology of cirrhosis — aetiology, trends and predictions	57
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications	57
Improving IBD outcomes in the era of many treatment options	56
Combination therapy with methotrexate in paediatric Crohn’s disease	55
Current developments in gastric cancer: from molecular profiling to treatment strategy	55
Resmetirom safe for nonalcoholic fatty liver disease	55
Elafibranor in primary biliary cholangitis	54
Promising results for exclusion diet in adults	53
New target and timing in PDAC immunotherapy?	53
Wound healing in the colon	53
Colonoscopy screening and risk of CRC	52
Filgotinib for ulcerative colitis	52
Discontinuation of infliximab in patients with Crohn’s disease on combination therapy	50
Hepatic IRF3 in glucose intolerance	46
Live bacterial therapeutics for detection and treatment of colorectal cancer	45
Targeting PARG in HCC	44
B cells in colonic mucosal healing	44
A pathway to therapy for HER2+ metastatic biliary tract cancer	43
Oral microbiome therapy efficacious for recurrent C. difficile infection	41
GWAS reveals variants for alcohol-related hepatocellular carcinoma	41
GLP1-mediated gut–brain neural circuit controls appetite suppression	41
Treating SBS with organoids	37
Digital twins are integral to personalizing medicine and improving public health	36
Ozanimod is efficacious in ulcerative colitis	36
Promising phase I interim results for CAR T cells in gastrointestinal cancers	34
Lenvatinib plus EGFR inhibition for liver cancer	33
EASL SLD Summit 2023	33
A resource for the food microbiome and its links with the human microbiome	31
Advancing on pancreatic cancer	31
Environmental enteric dysfunction: gut and microbiota adaptation in pregnancy and infancy	28
Intermittent fasting for NASH and HCC in mice	27
No excess cancer risk for non-erosive disease	27
Sex and ethnic disparities persist in hepatitis B management	27
The tumour-associated microbiome	26
Gut–brain axis key to fat preference	26
A distinct CD103+Vγ4+ γδ T cell subset is linked to lesion healing and improved prognosis	26
Incretin-based therapies for liver disease	26
Understanding HCC sex disparities	25
Digestive Disease Week 2023	24
A crucial Fusobacterium nucleatum clade in colorectal cancer	23
Metastatic pancreatic cancer and the liver	23
Targeting hyperactive tRNA modification improves anti-PD1 efficacy	23
Envisioning how to advance the MASH field	22
Food inequity and insecurity and MASLD: burden, challenges, and interventions	22
Etrasimod for ulcerative colitis: evaluating phase III results	22
Disease prevention trials in IBD: feasibility to future outlook	22
Standardized reporting of gastroenterology-related social media scholarship for career advancement	21
Evidence-based alcohol policies are the answer	21
Deciphering potential implications of dietary microplastics for human health	21
Gastric metaplasia could initiate the serrated neoplasia pathway in CRC	20
See the reality again in the field of liver transplantation	20
Combination therapies: the next major frontier in IBD management	20
Location, location, location — spatial insight into hepatic macrophage populations	20
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape	19
Benign liver tumours: understanding molecular physiology to adapt clinical management	19
Reply to ‘An expert panel Consensus Statement on ALD without experts by experience’	19
Bile acid transport inhibitors in paediatric hepatology: more than just an itch	19
Author Correction: Reply to: Postbiotics — when simplification fails to clarify	18
Liver fibrosis with methotrexate — an overestimated risk?	18
New understanding of hepatobiliary MRI	18
Unlocking the promise of RAS inhibition in pancreatic cancer	18
A deep dive into the submerged ‘coeliac iceberg’	17
Hepatitis C testing, treatment and prevention in low- and middle-income country prisons	17
Bacteriophages and their potential for treatment of gastrointestinal diseases	17
Safety of in utero exposure to maternal IBD pharmacotherapies	17
Ammonia-induced stress response in liver disease progression and hepatic encephalopathy	16
Novel interventions against alcohol-related liver disease	16
Toripalimab and chemotherapy in oesophageal squamous cell carcinoma	16
Mechanisms and pathophysiology of Barrett oesophagus	16
Shaping new paths in clinical trial design to address alcohol use disorders and alcohol-associated liver disease	15
PDAC: advances in tumour microenvironment, microbiome and AI	15
Decoding therapy resistance in liver tumours: a giant leap	15

The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	15
The maternal gut microbiome in pregnancy: implications for the developing immune system	14
The immune microenvironment in gastric adenocarcinoma	14
Friend or foe? The elusive role of hepatic stellate cells in liver cancer	14
Inflammatory bowel disease in pregnancy and breastfeeding	14
Regulation and functional roles of chemokines in liver diseases	13
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	13
ECCO’25	13
The pancreatic cancer genome revisited	13
Tango of B cells with T cells in the making of secretory antibodies to gut bacteria	13
Transport functions of intestinal lymphatic vessels	12
Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations	12
The global burden of coeliac disease: opportunities and challenges	11
The promise of the gut microbiome as part of individualized treatment strategies	11
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	11
Gut feelings: mechanosensing in the gastrointestinal tract	11
IL-12 and IL-23 pathway inhibition in inflammatory bowel disease	11
Dietary carbohydrates and fats in nonalcoholic fatty liver disease	11
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation	10
Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease	10
Cirrhosis-associated immune dysfunction	10
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics	10
Advancing the global public health agenda for NAFLD: a consensus statement	10
Hybrid ILC 2022	9
Positive phase III trials for ileal bile acid transporter inhibitors	9
Saliva — a new route for enteric viruses	9
Cellular stress and TH17 cell induction in the gut	8
Siderophore cross-feeding between fungi and Salmonella	8
Phage therapy alleviates NAFLD in mice	8
Gastrointestinal health and the environment: a bidirectional relationship	8
Tackling sorbitol intolerance	8
Biomarker shows no clinical use in guiding treatment for Crohn’s disease	8
Coeliac disease: complications and comorbidities	8
Fungi in Crohn’s disease and mucosal healing	8
Maralixibat relieves chronic cholestasis in children	7
A link to the past	7
Human liver tissue in a mouse host	7
Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome	7
Role of intestinal B cells in NASH and liver fibrosis	7
Upadacitinib therapy for Crohn’s disease	7
HDCA ameliorates NAFLD in mice	7
From stem to stern: LGR5+ as a marker for intestinal crypts	7
Catheter drainage in necrotizing pancreatitis	7
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	7
Lanifibranor and NASH resolution	7
COVID-19 and liver disease: where are we now?	7
Envisioning adalimumab for paediatric patients with ulcerative colitis	7
Consequences of bathroom restriction on transgender individuals with gastrointestinal conditions in the United States	6
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	6
Advancing health equity: The Association of Black Gastroenterologists and Hepatologists	6
Author Correction: A roadmap for clinical trials in MASH-related compensated cirrhosis	6
Medical therapy of paediatric inflammatory bowel disease	6
Genetics of irritable bowel syndrome: shifting gear via biobank-scale studies	6
Strengthening the foundation of African microbiome research: strategies for standardized data collection	6
Therapeutic base editing in the adult liver	5
Mother-to-child transmission of hepatitis B: current status and the road forward	5
The path to successful hepatitis C elimination in Spain	5
Bitter taste receptors as sensors of gut luminal contents	5
Probiotics for preterms: sharing complex decision-making	5
Implications of the evolving knowledge of the genetic architecture of MASLD	5
Post-surgical ctDNA in patients with CRC	4
Pancreatic cancer: why the cell of origin matters	4
Inflammation to cancer in PSC	4
Ultra-processed diet increases CRC risk	4
Adalimumab biosimilar comparable to originator in patients with advanced Crohn’s disease	4
Biological Gradient of Chronic Hepatitis B	4
Upgrading therapeutic ambitions and treatment outcomes	4
Applications of organoids in regenerative medicine: a proof-of-concept for biliary injury	4
C. difficile toxin strikes a nerve in the gut	4
Precision medicine in IBD: genes, drugs, bugs and omics	4
Black voices in gastroenterology and hepatology	4
Publisher Correction: Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis	4
Human duodenal cells contribute to liver regeneration	4
Sugemalimab with chemotherapy for advanced ESCC	4
Embracing many rainbows: the realities of being a gay physician, mother and patient	4
Nanoparticles in NAFLD therapeutics	3
Unravelling the genetics of irritable bowel syndrome	3
Characterizing the genomic landscape of colorectal cancer	3
Follow-up of SER-109 for recurrent C. difficile	3
CIDEB variants protect against liver disease	3
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	3
Microbiota-directed dietary supplement for children with acute malnutrition	3
Amitriptyline as second-line treatment for IBS in primary care settings	3
Development of MKK4 inhibitors for liver regeneration	3
Integrated systems approach to identify environmental factors in intestinal inflammation	3
Women in endoscopy: leading the way	3
Intercrypt goblet cells — the key to colonic mucus barrier function	3
MASH-induced senescence and liver cancer	3
HCV direct-acting antiviral therapy adherence in people who inject drugs	3
Linaclotide for functional constipation in paediatric patients: phase III results	3
Transglutaminase 2 inhibitor for coeliac disease	3
Investigating two versus three doses of mRNA vaccine in patients with cirrhosis	3
Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma	3
Break the taboo with poo	3
Intestinal HDL and liver injury	3